SCIENCE AND INNOVATION IN THE
EDUCATION SYSTEM
International scientific-online conference
48
FEATURES OF RELIEF OF UPPER RESPIRATORY TRACT DISEASES
INFECTED WITH COVID-19 IN PATIENTS WITH
ENDOCRINOLOGICAL DISEASES
Sadullayeva Rushana Sadullayevna
Bukhara State Medical Institute
https://doi.org/10.5281/zenodo.12730454
Clinical and epidemiological studies conducted during the COVID-19
pandemic prove the powerful negative impact of comorbid pathology on the
severity and outcomes of SARS-CoV-2 viral infection. Concomitant diseases that
are widespread and negatively affect the course of COVID-19 include
cardiovascular diseases and diabetes mellitus (DM).
The aim of the study
was to identify the features of the clinical and
metabolic status and disorders of carbohydrate metabolism in hospitalized
patients with the new coronavirus infection COVID-19 in combination with type
2 diabetes mellitus as the basis for optimizing glycemia management.
Materials and methods
was initiated in a temporary infectious diseases
hospital where 139 sequentially hospitalized patients with COVID-19 were
observed. All of them were initially considered as candidates for participation
and met the following criteria: 1) age ≥18 years, 2) informed voluntary consent
to participate, 3) COVID-19 is available, confirmed by a smear from the
nasopharynx and oropharynx, and 4) viral pneumonia by computed tomography
(CT). 57 of 139 patients were characterized by hyperglycemia upon admission.
Results and discussion among
139 hospitalized COVID-19 patients, the
most common comorbid pathology included hypertension (85 patients, or 61%),
obesity (58 people, or 41.7%), coronary heart disease (36 patients, or 25.9%)
and carbohydrate metabolism disorders (57 people, or 41%), including type 2
diabetes mellitus (42 (30.2%)), transient hyperglycemia ("conditional
prediabetes" (13 (9.4%)) and type 1 diabetes mellitus (2 cases (1.4%)).
At the same time, patients with concomitant type 2 diabetes mellitus (group 1)
were 2 times more likely to suffer from obesity (26 (61.9%) vs 25 (30.5%),
p=0.0008), 1.7 times more likely to suffer from hypertension (35 (83.3%) vs 41
(50.0%), p=0.0002) and 1.8 times more often with coronary heart disease (17
(40.5%) vs 18 (22.0%), p=0.026). Also, at the time of hospitalization, patients
with combined pathology were characterized by large volumes of lung damage
(according to computed tomography (CT) - 49.9±15.61% vs 42.1±19.13%,
p=0.017), a decrease in the initial level of SP2 (91.3±5.22% vs 93.6±3.71%,
p=0.008), high clinical scores risk on the SMRT-CO scale (2.5±1.09 vs 2.0±1.14,
SCIENCE AND INNOVATION IN THE
EDUCATION SYSTEM
International scientific-online conference
49
p=0.032). In dynamics, they showed a delayed recovery of respiratory disorders,
which was confirmed by a large volume of lung damage by CT at the end of
hospitalization (45.5±20.20% vs 32.0±15.93%, p=0.0007) and an extension of
the normalization period of SP2 (10.5± 7.15 vs 4.8±4.58 days, p=0.00001). As a
result, against the background of DM 2, COVID-19 patients needed longer
hospitalization (17.1±4.71 vs 14.8±5.10 days, p=0.009) and among them there
were more adverse outcomes in the form of ICU treatment and/or death (13
(31%) vs 12 (14.6%), p=0.030).
Conclusions
Among hospitalized COVID-19 patients, the most common
comorbid pathology includes hypertension (61%), obesity (46%), coronary
heart disease (25%) and carbohydrate metabolism disorders (41.7%), including
type 2 diabetes mellitus (30.2%), transient hyperglycemia (9.4%) and diabetes
mellitus Type 1 (1.4%). Patients with concomitant type 2 diabetes are 2 times
more likely to be obese, 1.7 times more likely to have hypertension and 1.8
times more likely to suffer from coronary heart disease.
References:
1. Kaiser UB, Mirmira RG, Stewart PM. Our response to COVID-19 as
endocrinologists and diabetologists. J Clin Endocr Metab. 2020;105(5):dgaa148.
Doi: 10.1210/clinem/dgaa148.
2. Boelaert K, Visser WE, Taylor PN, et al. Endocrinology in the time of COVID-
19: management of hyper- and hypo- thyroidism. EurJEndocrinol.
2020;183(1):G33–G39. Doi: 10.1530/EJE-20-0445.
3. Мокрышева Н.Г., Галстян Г.Р., Киржаков М.А., и др. Пандемия COVID-19 и
эндокринопатии // Проблемы эндокринологии. —2020. — Т.66. — №1.
[Mokrysheva NG, Galstyan GR, Kirzhakov MA, et al. Pandemiya COVID-19 i
endokrinopatii. Problemy endokrinologii. 2020;66(1). (In Russ.)].
